Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.

As of close of business last night, GoodRx Holdings Inc’s stock clocked out at $4.12, up 3.00% from its previous closing price of $4.0. In other words, the price has increased by $3.00 from its previous closing price. On the day, 3.46 million shares were traded. GDRX stock price reached its highest trading level at $4.1899 during the session, while it also had its lowest trading level at $3.95.

Ratios:

To gain a deeper understanding of GDRX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.09 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 7.55. For the most recent quarter (mrq), Quick Ratio is recorded 4.21 and its Current Ratio is at 4.21. In the meantime, Its Debt-to-Equity ratio is 0.85 whereas as Long-Term Debt/Eq ratio is at 0.84.

On December 04, 2024, Mizuho started tracking the stock assigning a Neutral rating and target price of $5. Raymond James Upgraded its Outperform to Strong Buy on August 09, 2024, while the target price for the stock was maintained at $10.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 05 ’25 when Spectrum Equity VII, L.P. sold 16,016 shares for $4.05 per share. The transaction valued at 64,865 led to the insider holds 0 shares of the business.

Spectrum VII Investment Manage bought 10,243 shares of GDRX for $40,972 on Sep 05 ’25. On Sep 05 ’25, another insider, Spectrum VII Co-Investment Fun, who serves as the Affiliate of the company, bought 5,773 shares for $4.00 each.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GDRX now has a Market Capitalization of 1431493888 and an Enterprise Value of 1697713920. As of this moment, GoodRx’s Price-to-Earnings (P/E) ratio for their current fiscal year is 44.40, and their Forward P/E ratio for the next fiscal year is 9.10. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.93. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.79 while its Price-to-Book (P/B) ratio in mrq is 2.26. Its current Enterprise Value per Revenue stands at 2.122 whereas that against EBITDA is 12.612.

Stock Price History:

The Beta on a monthly basis for GDRX is 1.24, which has changed by -0.46701163 over the last 52 weeks, in comparison to a change of 0.18189907 over the same period for the S&P500. Over the past 52 weeks, GDRX has reached a high of $8.06, while it has fallen to a 52-week low of $3.31. The 50-Day Moving Average of the stock is -8.52%, while the 200-Day Moving Average is calculated to be -9.06%.

Shares Statistics:

It appears that GDRX traded 3.00M shares on average per day over the past three months and 2658470 shares per day over the past ten days. A total of 99.90M shares are outstanding, with a floating share count of 81.48M. Insiders hold about 76.64% of the company’s shares, while institutions hold 15.77% stake in the company. Shares short for GDRX as of 1755216000 were 5365209 with a Short Ratio of 1.79, compared to 1752537600 on 5516302. Therefore, it implies a Short% of Shares Outstanding of 5365209 and a Short% of Float of 6.140000000000001.

Earnings Estimates

GoodRx Holdings Inc (GDRX) is presently subject to a detailed evaluation by 12.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is $0.1, with high estimates of $0.11 and low estimates of $0.08.

Analysts are recommending an EPS of between $0.4 and $0.34 for the fiscal current year, implying an average EPS of $0.38. EPS for the following year is $0.46, with 12.0 analysts recommending between $0.51 and $0.39.

Revenue Estimates

In the current quarter, 12 analysts expect revenue to total $195.17M. It ranges from a high estimate of $202.61M to a low estimate of $192.54M. As of the current estimate, GoodRx Holdings Inc’s year-ago sales were $195.25MFor the next quarter, 12 analysts are estimating revenue of $198.15M. There is a high estimate of $203.76M for the next quarter, whereas the lowest estimate is $194.1M.

A total of 14 analysts have provided revenue estimates for GDRX’s current fiscal year. The highest revenue estimate was $812.41M, while the lowest revenue estimate was $794.01M, resulting in an average revenue estimate of $798.73M. In the same quarter a year ago, actual revenue was $792.32MBased on 15 analysts’ estimates, the company’s revenue will be $841.92M in the next fiscal year. The high estimate is $871.41M and the low estimate is $816.1M.